BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 21898377)

  • 1. Dysfunctional transforming growth factor-β signaling with constitutively active notch signaling in Barrett's esophageal adenocarcinoma.
    Masuda S
    Cancer; 2012 Apr; 118(7):1956-7; author reply 1957-8. PubMed ID: 21898377
    [No Abstract]   [Full Text] [Related]  

  • 2. Dysfunctional transforming growth factor-β signaling with constitutively active Notch signaling in Barrett's esophageal adenocarcinoma.
    Mendelson J; Song S; Li Y; Maru DM; Mishra B; Davila M; Hofstetter WL; Mishra L
    Cancer; 2011 Aug; 117(16):3691-702. PubMed ID: 21305538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acidic fibroblast growth factor is expressed sequentially in the progression from Barrett's esophagus to esophageal adenocarcinoma.
    Soslow RA; Petersen CG; Remotti H; Altorki N
    Dis Esophagus; 2001; 14(1):23-7. PubMed ID: 11422301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ki-67 and Bax expression in esophageal mucosa might have implications in ablative therapies for Barrett's esophagus, dysplasia, and adenocarcinoma.
    Kountouras J; Chatzopoulos D; Zavos C; Deretzi G; Polyzos SA; Gavalas E; Klonizakis P; Vardaka E; Katsinelos P; Stergiopoulos C; Moschos J; Giartza-Taxidou E
    Surg Endosc; 2012 Jan; 26(1):283-4. PubMed ID: 21858571
    [No Abstract]   [Full Text] [Related]  

  • 5. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.
    Washington K; Chiappori A; Hamilton K; Shyr Y; Blanke C; Johnson D; Sawyers J; Beauchamp D
    Mod Pathol; 1998 Sep; 11(9):805-13. PubMed ID: 9758359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ski/SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus.
    Villanacci V; Bellone G; Battaglia E; Rossi E; Carbone A; Prati A; Verna C; Niola P; Morelli A; Grassini M; Bassotti G
    Hum Pathol; 2008 Mar; 39(3):403-9. PubMed ID: 18261624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinoic acid receptor-alpha messenger RNA expression is increased and retinoic acid receptor-gamma expression is decreased in Barrett's intestinal metaplasia, dysplasia, adenocarcinoma sequence.
    Lord RV; Tsai PI; Danenberg KD; Peters JH; Demeester TR; Tsao-Wei DD; Groshen S; Salonga D; Park JM; Crookes PF; Kiyabu M; Chandrasoma P; Danenberg PV
    Surgery; 2001 Mar; 129(3):267-76. PubMed ID: 11231454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of acidic fibroblast growth factor in Barrett's esophagus and associated esophageal adenocarcinoma.
    Soslow RA; Ying L; Altorki NK
    J Thorac Cardiovasc Surg; 1997 Nov; 114(5):838-43. PubMed ID: 9375615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinoma.
    Bobryshev YV; Freeman AK; Botelho NK; Tran D; Levert-Mignon AJ; Lord RV
    Dis Esophagus; 2010 Sep; 23(7):580-9. PubMed ID: 20459440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
    Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
    Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reply to letter to the editor: Re: Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies (Online First).
    Thrumurthy SG; Lewis CJ; Pritchard S; Armstrong G; Attwood SE
    Surg Endosc; 2012 Jan; 26(1):291-2. PubMed ID: 21853395
    [No Abstract]   [Full Text] [Related]  

  • 12. Toll-like Receptor 2 Signalling and the Lysosomal Machinery in Barrett's Esophagus.
    Verbeek RE; Siersema PD; Vleggaar FP; Ten Kate FJ; Posthuma G; Souza RF; de Haan J; van Baal JW
    J Gastrointestin Liver Dis; 2016 Sep; 25(3):273-82. PubMed ID: 27689189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Notch signaling drives development of Barrett's metaplasia from Dclk1-positive epithelial tuft cells in the murine gastric mucosa.
    Kunze B; Middelhoff M; Maurer HC; Agibalova T; Anand A; Bührer AM; Fang HY; Baumeister T; Steiger K; Strangmann J; Schmid RM; Wang TC; Quante M
    Sci Rep; 2021 Feb; 11(1):4509. PubMed ID: 33627749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pericentriolar material analyses in normal esophageal mucosa, Barrett's metaplasia and adenocarcinoma.
    Segat D; Cassaro M; Dazzo E; Cavallini L; Romualdi C; Salvador R; Vitale MP; Vitiello L; Fassan M; Rugge M; Zaninotto G; Ancona E; Baroni MD
    Histol Histopathol; 2010 May; 25(5):551-60. PubMed ID: 20238294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma.
    Hao Y; Triadafilopoulos G; Sahbaie P; Young HS; Omary MB; Lowe AW
    Gastroenterology; 2006 Sep; 131(3):925-33. PubMed ID: 16952561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.
    De Gottardi A; Dumonceau JM; Bruttin F; Vonlaufen A; Morard I; Spahr L; Rubbia-Brandt L; Frossard JL; Dinjens WN; Rabinovitch PS; Hadengue A
    Mol Cancer; 2006 Oct; 5():48. PubMed ID: 17054793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Notch signaling pathway in esophageal adenocarcinoma.
    Wang Z; Chen J; Capobianco AJ
    Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(6):24-32. PubMed ID: 26518893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma.
    Derks S; Nason KS; Liao X; Stachler MD; Liu KX; Liu JB; Sicinska E; Goldberg MS; Freeman GJ; Rodig SJ; Davison JM; Bass AJ
    Cancer Immunol Res; 2015 Oct; 3(10):1123-1129. PubMed ID: 26081225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
    Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation.
    Bailey T; Biddlestone L; Shepherd N; Barr H; Warner P; Jankowski J
    Am J Pathol; 1998 Jan; 152(1):135-44. PubMed ID: 9422531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.